kmk-vova/iStock via Getty Images
The US FDA has approved AbbVie’s Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis.
Approval was based on results from the phase 3 OptIMMize psoriasis clinical trial program.
A 55 mg pre-filled syringe has also been approved for patients weighing less than 40 kg.
Red Lobsters’ infamous $20 “Ultimate Endless Shrimp” promotion nearly sank the restaurant chain, now shareholders are alleging the promotion was...
Wall Street ended lower on Friday, with a steep drop in AI-related chip stocks and sharp gains in Moderna and...
Earnings Call Insights: Apogee Enterprises (APOG) Q1 fiscal 2027 Management View "Our team delivered revenue of $343 million and adjusted...
John Bolton, former national security advisor to President Donald Trump, pleaded guilty on Friday, June 26, to unlawfully retaining classified...
British Prime Minister Keir Starmer is resigning, and UK government bond yields are expressing modest relief.About the AuthorEconomics Editor at...
At 9 a.m. Eastern Time today, oil was priced at $73.74 per barrel with Brent serving as the benchmark (we’ll...
Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.
-1024x683.jpg "Strait Outta Hormuz: Getting the Iran Oil Story Straight")
